Skip Navigation

Richard Burkhart, M.D.

Richard Andrew Burkhart, M.D.

Headshot of Richard Burkhart
4.9out of 5
74 Ratings
  • Associate Professor of Surgery


Bile Duct Cancer, Bile Duct Disease, Bile Duct Repair, Bile Duct Surgery, Bile Duct Tumors, Biliary Tract Surgery, Biliary Tree, Colorectal Metastases to the Liver, Distal Pancreatectomy, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Cancers, Gastrointestinal Diseases, General Surgery, Hepatic Surgery, Hepatobiliary Disease, Hepatobiliary Malignancies, Hepatobiliary Surgery, Hepatocellular Carcinoma, Hepatopancreatobiliary Surgery, Klatskin Tumors, Laparoscopic Adrenal Surgery, Laparoscopic Cholecystectomy, Laparoscopic Gallbladder Surgery, Laparoscopic Liver Surgery, Laparoscopic Pancreas Surgery, Liver Cancer, Liver Cysts, Liver Tumors, Minimally Invasive Surgery, Neuroendocrine Tumors, Pancreatic Cancer, Pancreatic Cysts, Pancreatic Diseases, Pancreatic Surgery, Pancreatic Tumors, Pancreaticoduodenectomy, Retroperitoneal Sarcomas, Robotic Bilary Surgery, Robotic Liver Surgery, Robotic Pancreas Surgery, Stomach Cancer, Stomach Tumors, Surgical Oncology, Von Hippel-Lindau (VHL), Whipple Procedure more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


The Johns Hopkins Hospital

Appointment Phone: 443-997-1508
600 N. Wolfe Street
Blalock Building
Baltimore, MD 21287 map
Fax: 443-769-1276


Richard Burkhart, M.D., is an Assistant Professor of Surgery at The Johns Hopkins Hospital with a focus on complex minimally-invasive surgery and research for cancers of the pancreas, liver and bile ducts.

Dr. Burkhart received his medical degree from Boston University and completed his surgical residency and a research fellowship at the Thomas Jefferson University Hospital in Philadelphia. He is a member of several professional organizations, including the American Association of Cancer Research, the American College of Surgeons, the Society of Surgery for the Alimentary Tract, the Pancreas Club, and the Society of Surgical Oncology.

His current research focuses on precision medicine initiatives in cancer care.  He has a particular research interest in using personalized models of pancreas cancer, made from each patient’s tumor after surgical resection, to select the best chemotherapy in hopes of increasing survival and rates of cure. more



  • MD; Boston University School of Medicine (2008)


  • Surgery; Thomas Jefferson University Hospital (2015)


  • Surgical Oncology; Johns Hopkins University School of Medicine (2017)

Board Certifications

  • American Board of Surgery (Surgery) (2015)
  • American Board of Surgery (Surgical Oncology) (2019)

Research & Publications

Selected Publications

Burkhart RA, Relles D, Pineda DM, Gabale S, Sauter PK, Rosato EL, Koniaris LG, Lavu H, Kennedy EP, Yeo CJ, Winter JM. Defining treatment and outcomes of hepaticojejunostomy failure following pancreaticoduodenectomy. J Gastrointest Surg. 2013 Mar;17(3):451-60.

Burkhart RA, Peng Y, Norris ZA, Tholey R, Talbott VA, Liang Q, Ai Y, Miller K, Lal S, Cozzitorto JA, Witkiewicz AK, Yeo CJ, Gehrmann M, Napper A, Winter JM, Sawicki JA, Zhuang Z, Brody JR. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival. Molecular Cancer Research. 2013 Aug;11(8):901-11.

Burkhart RA, Pineda DM, Chand SN, Romeo C, Londin ER, Karoly ED, Cozzitorto JA, Rigoutsos I, Yeo CJ, Brody JR, Winter JM.  HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. RNA Biology. 2013 Aug 1;10(8):1312-23.

Burkhart RA, Tholey RM, Guinto D, Yeo CJ, Chojnacki K. Grit: A marker for residents at risk for attrition? Surgery. 2014 Jun; 155(6): 1014-22.

Burkhart RA, Gerber SM, Tholey RM, Lamb K, Somasundaram A, McIntyre C, Fradkin E, Ashok A, Felte R, Mehta J, Rosato EL, Lavu H, Jabbour SA, Yeo CJ, Winter JM. Incidence and severity of pancreatogenic diabetes after pancreatic resection. J Gastrointest Surg. 2015 Feb; 19(2): 217-25.

Burkhart RA, Laheru D, Herman J, Pawlik T. Multidisciplinary management and the future of treatment in cholangiocarcinoma. Expert Opinion on Orphan Drugs. 2016 Mar; 4(3): 255-67.

Burkhart RA, Pawlik TM. Personalized therapy in hepatocellular carcinoma: molecular markers of prognosis and therapeutic response. Surgical Oncology. 2017 Jun; 26(2): 138-145.

Burkhart RA, Javed AA, Ronnekleiv-Kelly S, Wright MJ, Poruk KE, Eckhauser F, Makary MA, Cameron JL, Wolfgang CL, He J, Weiss MJ. The use of negative pressure wound therapy to prevent post-operative surgical site infections following pancreaticoduodenectomy. HPB. 2017 Jun; [EPUB]

Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, Maiorino L, Tiriac H, Young CM, Miyabayashi K, Filippini D, Creighton B, Burkhart RA, Buscaglia JM, Kim EJ, Grem JL, Lazenby AJ, Grunkemeyer JA, Hollingsworth MA, Grandgenett PM, Egeblad M, Park Y, Tuveson DA, Vakoc CR. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell. 2017 Jul 25. [EPUB]

Activities & Honors


  • Trustee Scholar Award, Boston University, 2002
  • Research Scholar Award, Arnold and Mabel Beckman Foundation, 2002
  • Honors in Biomedical Engineering, Summa Cum Laude, Boston University, 2004
  • Elected to Scarlet Key Society, Boston University, 2009
  • Resident Teaching Award, Department of Surgery, Thomas Jefferson University Hospital, 2009
  • Resident Research Award, Department of Surgery, Thomas Jefferson University Hospital, 2012
  • Chief Administrative Fellow, Division of Surgical Oncology, Department of Surgery, The Johns Hopkins Hospital, 2016


  • American College of Surgeons, 2009
  • American Association of Cancer Research, 2011
  • Pancreas Club, 2011
  • Society for Surgery of the Alimentary Tract, 2013
  • Society of Surgical Oncology, 2015

Videos & Media

Play Video:

Treating Benign and Malignant Liver Tumors | FAQs with Dr. Richard Burkhart

Lectures and Presentations

  • “Behind the Warburg effect: RNA-binding protein, HuR, can regulate pancreatic cancer cell metabolism”
    Oral Presentation, 7th Annual Academic Surgical Congress, Las Vegas, NV (01/01/2012)
  • “From test tubes to cells: A systematic, rational discovery of an FDA approved drug for the targeted treatment of pancreatic cancer”
    Oral Presentation, 46th Annual Pancreas Club, San Diego, CA (01/01/2012)
  • “Maximizing resident retention by studying grit in surgical trainees”
    Oral Presentation, 14th Annual Surgical Education Week, Chicago, IL (01/01/2014)
  • “The incidence of pancreatogenic diabetes after major partial pancreatic resection may be greater than you think.”
    Oral Presentation, 48th Annual Pancreas Club, Chicago, IL (01/01/2014)
  • “The use of negative pressure wound therapy to prevent post-operative surgical site infections following pancreaticoduodenectomy (PD)”
    Oral Presentation, Americas Hepato-Pancreato-Biliary Association Annual Meeting, Miami Beach, FL (01/01/2017)

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • 4.9 Provider Explained Things Clearly
  • 5.0 Provider Listened Carefully
  • 4.9 Provider Knew Medical History
  • 5.0 Provider Showed Respect
  • 4.9 Provider Spent Enough Time
  • 4.9 Overall Rating by Patient


4.9 out of 5 (74 Ratings, 35 Comments)
    Is this you? Edit Profile
    back to top button